NovoCure (NVCR) Share-based Compensation (2014 - 2026)

NovoCure has disclosed Share-based Compensation across 13 years of filings, most recently posting $63.0 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $63.0 million, up 113.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $138.3 million (down 11.07% YoY), and the FY2025 annual result was $104.8 million, down 34.49% from the prior year.
• Share-based Compensation came in at $63.0 million for Q1 2026 at NovoCure, up from $19.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $63.0 million in Q1 2026 to a low of $17.4 million in Q4 2023.
• The 5-year median for Share-based Compensation is $29.6 million (2025), against an average of $32.4 million.
• Across the five-year window, Share-based Compensation soared 259.89% in 2024 and sank 68.42% in 2025, its largest moves.
• NovoCure's Share-based Compensation stood at $29.8 million in 2022, then tumbled by 41.45% to $17.4 million in 2023, then jumped by 259.89% to $62.8 million in 2024, then tumbled by 68.42% to $19.8 million in 2025, then jumped by 217.97% to $63.0 million in 2026.
• The last three Share-based Compensation figures came in at $63.0 million (Q1 2026), $19.8 million (Q4 2025), and $29.3 million (Q3 2025), per Business Quant data.